Veritas In Silico Inc.
130A・Growth Market・Pharmaceuticals
Veritas In Silico Inc.130A
Recent Disclosures
| Date | Type | Title |
|---|---|---|
| 2026-11-16 | Other | 筋萎縮性側索硬化症(ALS)の治療に向けた新たな核酸医薬品に関する特許権利化のお知らせ |
| 2026-11-16 | Other | Announcement of Patent Grant for a Novel Nucleic Acid Therapeutic for Amyotrophic Lateral Sclerosis (ALS) |
| 2026-11-11 | Other | FY2026 Third Quarter Financial Briefing Materials |
| 2026-11-11 | Earnings Report | 2026年12月期 第3四半期決算短信〔日本基準〕(非連結) |
| 2026-11-11 | Other | 2026年12月期第3四半期 決算説明資料 |
| 2026-11-11 | Other | Non-consolidated Financial Results for the Nine Months Ended September 30, 2026 [Under Japanese GAAP] |
| 2026-11-11 | Other | Revised Financial Forecast for the Fiscal Year Ending December 31, 2026 |
| 2026-11-11 | Other | 2026 年12月期 通期業績予想の修正に関するお知らせ |
| 2026-11-11 | Other | Completion of Pre-development Consultation with PMDA and Future Prospects for Proprietary Drug Delivery System "Perfusio(R)" |
| 2026-11-11 | Other | ドラッグデリバリーシステム「Perfusio(R)(パーフュージオ(R))」PMDA開発前相談の終了と今後の展望について |

